The prognostic and predictive value of serum CA19.9 in pancreatic cancer

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1713-1722

  Humphris, J L ^a   Chang, D K ^a,b,c   Johns, A L ^a   Scarlett, C J ^a,d   Pajic, M ^a   Jones, M D ^a   Colvin, E K ^a   Nagrial, A ^a   Chin, V T ^a   Chantrill, L A ^a   Samra, J S ^e   Gill, A J ^e,f   Kench, J G ^a,f,g   Merrett, N D ^b,h   Das, A ^b   Musgrove, E A ^a,i   Sutherland, R L ^a,i   Biankin, A V ^a,b,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF WESTERN SYDNEY   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adjuvant chemotherapy; CA19.9; Pancreatic cancer; Prognosis

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 84861608121     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr561     Document Type: Article

References (37)

1. Butturini G, Stocken DD, Wente MN et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83. discussion 83.
2. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[erratum appears in N Engl J Med. 2004; 351 (7): 726]. N Engl J Med 2004; 350:1200-1210
3. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. [erratum appears in JAMA. 2008; 299 (16): 1902]. JAMA 2008; 299: 1019-1026.
4. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
5. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.
6. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-55.
7. Koprowski H, Steplewski Z, Mitchell K et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971.
8. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-270.
9. Boeck S, Stieber P, Holdenrieder S et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255-264.
10. Biankin AV, Kench JG, Colvin EK et al. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009;137: 558-568.
11. Chang DK, Johns AL, Merrett ND et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009; 27: 2855-2862.
12. Edge SB, Byrd DR, Compton CC et al.AJCC Cancer Staging Manual 2010New YorkSpringer
13. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-955. discussion 955-956
14. Kim YC, Kim HJ, Park JH et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. J Gastroenterol Hepatol 2009; 24: 1869-1875.
15. Kang CM, Kim JY, Choi GH et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007; 140: 31-35.
16. Le Pendu J, Marionneau S, Cailleau-Thomas A et al. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001; 109: 9-31.
17. Vestergaard EM, Hein HO, Meyer H et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999; 45: 54-61.
18. Tempero MA, Uchida E, Takasaki H et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47: 5501-5503.
19. Orntoft TF, Vestergaard EM, Holmes E et al. Influence of Lewis alpha1-3/4-Lfucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J Biol Chem 1996; 271: 32260-32268.
20. Ong SL, Sachdeva A, Garcea G et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008; 53: 3213-3217.
21. Mann DV, Edwards R, Ho S et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000; 26: 474-479.
22. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45: 253-259.
23. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994; 9: 731-734.
24. Nakao A, Oshima K, Nomoto S et al. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 1998; 15: 15-22.
25. Barton JG, Bois JP, Sarr MG et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 2009; 13: 2050-2058.
26. Turrini O, Schmidt CM, Moreno J et al. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?. J Gastrointest Surg 2009; 13: 1791-1797.
27. Montgomery RC, Hoffman JP, Riley LB et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997; 4: 551-556.
28. Ferrone CR, Finkelstein DM, Thayer SP et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24: 2897-2902.
29. Berger AC, Garcia M, Jr, Hoffman JP et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922.
30. Kondo N, Murakami Y, Uemura K et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010; 17: 2321-2329.
31. Kinsella TJ, Seo Y, Willis J et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008; 31: 446-453.
32. Hernandez JM, Cowgill SM, Al-Saadi S et al. CA 19-9 velocity predicts diseasefree survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009; 13: 349-353.
33. Maisey NR, Norman AR, Hill A et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005; 93: 740-743.
34. Reni M, Cereda S, Balzano G et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-2639.
35. Wong D, Ko AH, Hwang J et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008; 37: 269-274.
36. Ali CW, Kaye TF, Adamson DJA et al. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. J Gastrointest Cancer 2007; 38: 108-114.
37. Hess V, Glimelius B, Grawe P et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132-138.